Ascendis Wins FDA Approval For Rare Disease Therapy

Ascendis Pharma A/S shares are up during Monday’s premarket league pursuing the FDA’s support of Yuviwel (navepegritide; developed arsenic TransCon CNP), the archetypal and lone once-weekly attraction for children with achondroplasia.

The FDA approved Yuviwel, a prodrug designed to summation linear maturation successful children aged 2 years and older with achondroplasia, based connected information from 3 randomized objective trials.

Achondroplasia is simply a uncommon familial upset causing dwarfism, characterized by abbreviated limbs, a normal-sized torso, and a ample head.

Ascendis Pharma plans to marque Yuviwel disposable done prescribing physicians successful the U.S. during the aboriginal portion of the 2nd 4th of 2026.

Don't Miss:

• Explore the Fire-Safe Energy Storage Company With $185M successful Contracted Revenue

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In astatine $0.85/Share

In November, Ascendis Pharma announced that pivotal week 52 results from its ApproaCH Trial of investigational once-weekly TransCon CNP (navepegritide) successful children with achondroplasia person been published successful JAMA Pediatrics, a diary of the American Medical Association.

The authors study that attraction with TransCon CNP led to importantly higher annualized maturation velocity (AGV) astatine week 52 compared to placebo (primary endpoint), arsenic good arsenic improved lower-limb alignment and assemblage proportionality and affirmative changes successful health-related prime of life, with a information and tolerability illustration akin to placebo.

Additionally, the support includes a Rare Pediatric Disease Priority Review Voucher, which could expedite aboriginal cause applications. This improvement marks a important advancement successful attraction options for a information that affects galore children, providing a caller avenue for maturation successful Ascendis Pharma’s portfolio.

Trending: Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights

The banal is presently trading 0.42% beneath its 20-day elemental moving mean (SMA) and 2.45% supra its 100-day SMA, indicating immoderate short-term weakness but longer-term strength. Over the past 12 months, shares person accrued importantly and are presently positioned person to their 52-week highs than lows.

The RSI is astatine 50.00, which is considered neutral territory, suggesting that the banal is neither overbought nor oversold astatine this time. Meanwhile, MACD is astatine 0.15, beneath its awesome enactment astatine 0.22, indicating bearish unit connected the stock. The operation of neutral RSI and bearish MACD suggests mixed momentum.